Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
VERSED (midazolam) is an oral syrup small-molecule benzodiazepine approved in 1998 for sedation and anxiolysis. The drug acts as a central nervous system depressant via GABA receptor modulation. It is commonly used in perioperative settings and pediatric procedures.
Competitive pressure at 30% indicates moderate market challenge; brand team likely focused on lifecycle extension and retention strategies rather than growth.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Tornier Perform™ Reversed Monopost Study
Shoulder iD™ Primary Reversed Glenoid Outcomes Clinical Study
Can INSTI-associated Weight Gain be Halted or Reversed With a Switch to Doravirine/Lamivudine/Tenofovir DF?
TRAP Intervention STudy: Early Versus Late Intervention for Twin Reversed Arterial Perfusion Sequence
How Quickly Can the Effects of Excessive Caloric Intake on Insulin Resistance be Reversed?
Worked on VERSED at Roche? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Roche is hiring 2 roles related to this product
Working on VERSED offers stability in a mature, established product with decades of clinical validation, but limited growth trajectory. The approaching LOE creates urgency around defensive strategies, making this a role suited for professionals skilled in cost management, generic competition response, and lifecycle extension.